醋酸阿比特龙片致低血钾症1例分析

doi:10.19803/j.1672-8629.20240757

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (11): 1296-1299.
DOI: 10.19803/j.1672-8629.20240757

醋酸阿比特龙片致低血钾症1例分析

任桂玲¹, 苏长海¹, 王星¹, 陈刚¹, 鄢秋强², 杨俊丽^1*

¹鄂尔多斯市中心医院药剂科,内蒙古鄂尔多斯 017000;
²内蒙古医科大学口腔医学院,内蒙古呼和浩特 010059

收稿日期:2024-09-27 出版日期:2025-11-15 发布日期:2025-11-14
通讯作者: ^*杨俊丽,女,硕士,主任药师,临床药学。E-mail: yangjunli416@163.com
作者简介:任桂玲,女,硕士,主管中药师,临床药学。
基金资助:
鄂尔多斯市财政资助医学重点学科建设（鄂卫健发〔2020〕230号）

One Case of Hypokalemia Caused by Abiraterone Actae Tablets

REN Guiling¹, SU Changhai¹, WANG Xing¹, CHEN Gang¹, YAN Qiuqiang², YANG Junli^1*

¹Department of Pharmacy, Erdos Central Hospital, Erdos Inner Mongolia 017000, China;
²College of Stomatology, Inner Mongolia Medical University, Hohhot Inner Mongolia 010059, China

Received:2024-09-27 Online:2025-11-15 Published:2025-11-14

摘要/Abstract

摘要： 目的探讨醋酸阿比特龙片（简称“阿比特龙”）诱发低血钾症致四肢无力的病例,为阿比特龙的安全使用提供参考。方法分析1例74岁男性前列腺癌患者使用阿比特龙诱发低血钾症致四肢无力的不良反应,对相关文献进行归纳与总结,梳理阿比特龙致低血钾症的作用机制和防治措施。结果临床药师结合病史及用药史,考虑患者四肢无力可能与阿比特龙致低血钾相关。通过对症治疗、优化治疗方案,患者血钾水平恢复正常、肌无力症状好转。结论医护人员应强调患者在使用阿比特龙的同时规律服用醋酸泼尼松片,并定期（至少每月1次）监测血钾水平,以便及时发现并处理相关不良反应,保障患者用药安全。

关键词: 醋酸阿比特龙片, 低血钾症, 四肢无力, 醋酸泼尼松片, 药品不良反应

Abstract: Objective To study limb weakness caused by abiraterone-induced hypokalemia so as to provide references for safe use of abiraterone. Methods One case of limb weakness due to abiraterone-induced hypokalemia in a 74-year-old male patient with prostate cancer was analyzed. Related literature was retrieved to explore the mechanism of action, incidence and precautions related to abiraterone-induced hypokalemia. Results The clinical pharmacist took into consideration the history of disease and medications and concluded that the patient's limb weakness might be related to hypokalemia caused by abiraterone. After symptomatic treatment and optimization of treatment plans, the patient's blood potassium level returned to normal, and the symptoms of muscle weakness improved. Conclusion Clinicians should remind patients to take prednisone regularly while they take abiraterone, and monitor the blood potassium levels regularly (at least once a month) so as to detect and manage related adverse reactions quickly and ensure the safety of patients.

Key words: Abiraterone Acetate Tablets, Hypokalemia, Weakness of Limbs, Prednisone, Adverse Drug Reaction

中图分类号:

任桂玲, 苏长海, 王星, 陈刚, 鄢秋强, 杨俊丽. 醋酸阿比特龙片致低血钾症1例分析[J]. 中国药物警戒, 2025, 22(11): 1296-1299.

REN Guiling, SU Changhai, WANG Xing, CHEN Gang, YAN Qiuqiang, YANG Junli. One Case of Hypokalemia Caused by Abiraterone Actae Tablets[J]. Chinese Journal of Pharmacovigilance, 2025, 22(11): 1296-1299.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240757

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I11/1296

参考文献

[1] General Office of the National Health Commission. Prostate Cancer Diagnosis and Treatment guidelines[EB/OL]. (2022-04-03)[2025-03-10]. http://www.nhc.gov.cn/yzygj/s7659/202204/a0e67177df1f439898683e1333957c74.shtml.
[2] Chinese Clinical Oncology Guideline Committee. CSCO Guidelines for Diagnosis and Treatment of Common Malignant Tumors 2023(中国临床肿瘤学会CSCO常见恶性肿瘤诊疗指南2023)[M]中国临床肿瘤学会CSCO常见恶性肿瘤诊疗指南2023)[M]. Beijing: People's Medical Publishing House, 2023: 421-460.
[3] Chengdu Shengdi Pharmaceutical Co., Ltd. Drug Instructions for Abiraterone Tablets[EB/OL]. (2022-04-20)[2024-10-29]. https://db.yaozh.com/instruct?comprehensivesearchcontent=%E9%86%8B%E9%85%B8%E9%98%BF%E6%AF%94%E7%89%B9%E9%BE%99%E7%89%87.
[4] ZHANG XY, KONG WQ, ZHONG H, et al.Research on Adverse Event Signals of Abiraterone Based on FAERS DATABASe[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(10): 1148-1153, 1172.
[5] NKWOCHA BI, SINGH M.Abiraterone-Induced Hypokalemia: a Case Report[J]. Cureus, 2023, 15(7): e42533.
[6] YAMAMOTO Y, AKASHI Y, MINAMI T, et al.Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer[J]. Urology Case Reports, 2018, 2018: 1414395.
[7] MAO J, CHANG AK, CHIN S, et al.Polymorphic Ventricular Tach-ycardia and Cardiac Arrest from Abiraterone-Induced Hypokalemia: a Case Report[J]. Journal of Medical Case Reports, 2024, 18(1): 186.
[8] RIAD M, ALLISON JS, NAYYAL S, et al. Abiraterone-Induced Refractory Hypokalaemia and Torsades De Pointes in a Patient with Metastatic Castration-Resistant Prostate Carcinoma: a Case Report[J]. European Heart Journal-Case Reports, 2021, 5(12): ytab462.
[9] KHAN A, KNEALE B.Life Threatening Torsades De Pointes Due to Abiraterone-Induced Hypokaelemia in a Patient with Metastatic Prostate Cancer[J]. The New Zealand Medical Journal, 2016, 129(1445): 124-127.
[10] SHAFFI SK, RAVENDER R, KODAVANTI CKM, et al.Abira-terone-Associated Mineralocorticoid Excess: a Case Report[J]. Cureus, 2024, 16(1): e51757.
[11] BETSIKOS A, PASCHOU E, GELADARI V, et al.Abiraterone-Induced Secondary Hypertension: Two Wrongs Don't Make a Right[J]. Cureus, 2024, 16(5): e60299.
[12] CHENG HG, LI XW, GOU X.Selection of New Type Endocrine Drugs for Special Population with Prostate Cancer[J]. Chongqing Medicine(重庆医学), 2022, 51(16): 2866-2869.
[13] ZHANG YN, YANG HX, ZHANG L, et al.Comparative Evaluation of the Correlation between Naranjo's Assessment Scale and the Judgment Criteria of the National Center for Adverse Drug Reaction Monitoring on the Association of Drospirenone and Ethinylestradiol Tablets with Pulmonary Embolism[J]. Journal of Disease Monitor and Control(疾病监测与控制), 2023, 17(6): 430-434.
[14] ZHAO ZH, MAO Y, JIANG W, et al.A Case of Severe Hypokalemia with Tip-Twisting Ventricular Tachycardia Caused by Oral Prednisone[J]. Chinese Circulation Journal(中国循环杂志), 2008, 23(5): 323.
[15] SHPILSKY J, STEVENS J, BUBLEY G.An Up-to-Date Evaluation of Abiraterone for the Treatment of Prostate Cancer[J]. Expert Opin Pharmacother, 2021, 22(10): 1227-1234.
[16] SHEN YK, GONG RX, XIE YL, et al.Cost-Utility Analysis of Abiraterone as First-Line Treatment for Metastatic Castration-Resistant Prostate Cancer[J]. Evaluation and Analysis of Drug-Use in Hospitals(中国医院用药评价与分析), 2023, 23(11): 1363-1368.
[17] DANILA DC, MORRIS MJ, DE-BONO JS, et al.Phase ⅡMul-ticenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients with Docetaxel-Treated Castration-Resistant Prostate Cancer[J]. Journal of Clinical Oncology, 2010, 28(9): 1496-1501.
[18] LIU M, SHI YF, LE KD, et al.To Compare the Efficacy and Safety of Generic and Original Abiraterone in the Treatment of Advanced Prostate Cancer[J]. Evaluation and Analysis of Drug-Use in Hospitals(中国医院用药评价与分析), 2023, 23(6): 696-700.
[19] DECAMPS S, LIS R, EKANAYAKE P. Abiraterone-Induced Endocrinopathies[J]. Journal of Clinical Endocrinology & Metabolism, 2023, 1(2): luad039.
[20] STERNBERG CN, CASTELLANO D, DAUGAARD G, et al.Abiraterone Acetate for Patients with Metastatic Castration Resistant Prostate Cancer Progressing after Chemotherapy: Final Analysis of a Multicentre, Open-Label, Early Access Protocol Trial[J]. Lancet Oncol, 2014, 15(11): 1263-1268.
[21] RYAN CJ, SMITH MR, FIZAZI K, et al.Abiraterone Acetate Plus Prednisone Versus Placebo Plus Prednisone in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer (COU-AA-302): Final Overall Survival Analysis of a Randomised, Double-Blind, Placebo-Controlled Phase 3 Study[J]. Lancet Oncol, 2015, 16(2): 152-160.
[22] FIZAZI K, TRAN N, FEIN L, et al.Abiraterone Plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer[J]. The New England Journal of Medicine, 2017, 377(4): 352-360.
[23] Chinese Committee for the Revision of Guidelines for the Prevention and Treatment of Hypertension, Hypertension Alliance (China), Hypertension Committee of Chinese Medical Care for International Exchange and Promotion, et al. Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 Revision)[J]. Chinese Journal of Hypertension(中华高血压杂志), 2024, 32(7): 603-700.
[24] DINSEN S, BASLUND B, KLOSE M, et al.Why Glucocorticoid Withdrawal May Sometimes Be As Dangerous as the Treatment Itself[J]. European Journal of Internal Medicine, 2013, 24(8): 714-720.

醋酸阿比特龙片致低血钾症1例分析

One Case of Hypokalemia Caused by Abiraterone Actae Tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	蒋晓峰, 杨淑婷, 白丽琴, 戚俊, 何建雄, 陈文戈, 梁祖红, 李渔, 余晓霞. 医疗机构制剂不良反应监测与评价系统构建及初步实践[J]. 中国药物警戒, 2025, 22(9): 1008-1011.
[2]	蔡杰, 韩陈媛, 江君微. 887例静脉滴注抗菌药物不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1018-1023.
[3]	郑金凤, 吴佳妮, 林京玉, 杨雪卿. 222例口服凝血因子Xa抑制剂不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1024-1028.
[4]	谢加力, 荀艳, 陶云松, 章圣朋. 211例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1029-1033.
[5]	刘芹, 章嘉一, 吴烜, SOANES Nigel. 基于生成式人工智能大语言模型的文献来源药品不良反应报告自动生成平台研究与应用[J]. 中国药物警戒, 2025, 22(9): 1040-1044.
[6]	李舒悦, 邱慧颖, 吴佳琪, 高君伟. 炔雌醇环丙孕酮片致急性髓系白血病患者血小板减少期间血栓形成2例分析[J]. 中国药物警戒, 2025, 22(9): 1045-1048.
[7]	李丹, 阳雄文, 陈丹君, 付成效, 阳波. 苯扎贝特片致慢性肾病患者横纹肌溶解1例分析[J]. 中国药物警戒, 2025, 22(9): 1049-1050.
[8]	钱凤丹, 张立超, 贡翊斐. 注射用尖吻蝮蛇血凝酶致严重过敏性休克1例分析[J]. 中国药物警戒, 2025, 22(9): 1051-1053.
[9]	邵一帆, 陈秋岑, 翟惠奇, 吴伟, 褚庆民. 铝碳酸镁咀嚼片致严重过敏反应1例分析[J]. 中国药物警戒, 2025, 22(9): 1054-1056.
[10]	魏盈, 李文凤, 张宇飞, 侯欣, 杨彦伟, 樊永丽. 度伐利尤单抗注射液致脓疱型银屑病1例分析[J]. 中国药物警戒, 2025, 22(9): 1057-1060.
[11]	李明颖, 张晓霞, 孙晓黎, 赵燕, 何苗, 李艳玲, 段薇, 杨鸥. 舒更葡糖钠对腹腔镜全盆底重建术后患者恢复的影响[J]. 中国药物警戒, 2025, 22(8): 896-901.
[12]	柯秀琴, 海学武. 433例羟苯磺酸钙胶囊不良反应分析[J]. 中国药物警戒, 2025, 22(8): 924-927.
[13]	梁洁. 172例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(8): 928-932.
[14]	赵牡丹, 朱明辉, 张欢, 赵远洋, 秦靖. 1例彭氏变形杆菌致糖尿病足感染的药学监护[J]. 中国药物警戒, 2025, 22(8): 937-940.
[15]	周玗洁, 黄晓婧, 陈明月, 杜鹏强, 王爱凤. 注射用头孢哌酮舒巴坦钠致重度血小板减少2例分析[J]. 中国药物警戒, 2025, 22(8): 941-943.